This clinical trial is focused on studying a condition known as Primary Immune Thrombocytopenia (ITP), which is a disorder that can lead to easy or excessive bruising and bleeding due to low levels of platelets in the blood. The study aims to compare the effectiveness and safety of two different treatments for patients who have been newly diagnosed with this condition. The treatments being compared are a combination of romiplostim and dexamethasone, versus dexamethasone alone. Romiplostim is a medication that helps increase platelet production, while dexamethasone is a type of steroid that can reduce inflammation and modify the body’s immune response.

The purpose of the study is to evaluate whether the combination of romiplostim and dexamethasone is more effective than dexamethasone alone in achieving a sustained response in patients, meaning that their platelet levels remain stable without the need for additional ITP treatments. The study will observe patients over a period of time to see if they can maintain healthy platelet levels and avoid significant bleeding episodes. Participants will receive either the combination treatment or dexamethasone alone, and their progress will be monitored by healthcare professionals.

Throughout the study, patients will be regularly assessed to ensure their safety and to track the effectiveness of the treatments. The study will last for several months, with the goal of determining which treatment option provides the best long-term results for individuals with newly diagnosed primary immune thrombocytopenia. This research is important for improving treatment strategies and outcomes for people affected by this condition.